Charcot-marie-tooth (CMT) disease is caused by mutations in the genes that affect the structure and function of peripheral nerves that control movement and sensation. Defective genes can cause the nerve fibers (axons) or myelin sheaths (the fat layer that separates nerve fibers) to degenerate in the peripheral nerves. This weakens the transmission of nerve signals between the brain and limbs, causing muscle atrophy and decreased sensation. As charcot-marie-tooth disease progresses, symptoms will spread from the feet and legs to the hands and arms.
The severity of symptoms (that includes weakness in the legs, ankles, and feet, decreased muscle mass in the legs and feet, high foot arches, curled toes (hammer toes), and decreased walking and running ability, among others) varies from person to person, including between family members. The different types and subtypes of CMT are determined based on the mutant gene, genetic type, nerve conduction velocity, age of onset, disease severity, clinical symptoms, and peripheral nerve injury. The different types of CMT diseases include CMT1, CMT2, CMT3, CMT4, CMTX, and DICMT.
Market Dynamics
Increasing prevalence of charcot-marie tooth disease is one major factor driving the market growth. For instance, according to a data published by the Medscape in January 2021, the prevalence of CMT disease is one in 2,500 population, which is approximately 125,000 people in the U.S. The incidence of CMT 1 is 15 per 100,000 population; the incidence of CMT 1A is 10.5 per 100,000 population, or 70% of CMT 1. The incidence of CMT 2 is seven per 100,000 people. CMT X patients account for at least 10-20% of CMT syndrome patients.
Key features of the study:
- This report provides in-depth analysis of the global charcot-marie-tooth disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global charcot-marie-tooth disease market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global charcot-marie-tooth disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global charcot-marie-tooth disease market
Detailed Segmentation:
- Global Charcot-Marie-Tooth Disease Market, By Disease Type:
- Global Charcot-Marie-Tooth Disease Market, By Drug Type:
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- Global Charcot-Marie-Tooth Disease Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Charcot-Marie-Tooth Disease Market, By Region:
- North America
- By Disease Type
- By Drug Type
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Disease Type
- By Drug Type
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Disease Type
- By Drug Type
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Disease Type
- By Drug Type
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Disease Type
- By Drug Type
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Disease Type
- By Drug Type
- Nonsteroidal anti-inflammatory drugs
- Cyclooxygenase-2 inhibitors
- Tricyclic antidepressants
- Anticonvulsants
- Analgesics
- Pipeline Drug
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Addex Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Affectis Pharmaceuticals AG
- Genzyme Corp
- Lead Discovery Center GmbH
- Pharnext SA
- Acceleron Pharma
- MedDay Pharmaceuticals
- Bristol-Myers-Squibb Company
- Inflectis Bio Science Health Company
- Helixmith Co., Ltd.
- Neurogene Inc.
“*” marked represents similar segmentation in other categories in the respective section.
